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1.1. Introduction of AMPK
The heterotrimeric protein, AMPK, plays a pivotal regulatory role
in cellular energy homeostasis and metabolism. This serine/
threonine kinase is formed by a catalytic subunit α and two
regulatory subunits β and γ1–3. Each subunit has its own isoforms
and binds different ligands. As an example, for decreasing the
activity of AMPK, adenosine triphosphate (ATP) could be bound
with in an opposite manner, while adenosine diphosphate (ADP)
could bind with the γ subunit for protecting AMPK via Thr-172
dephosphorylation1,4. These AMPK subunit isoforms could com-
bine or interact with each other, which might form about 12
heterotrimers in different tissues5,6. Furthermore, activated AMPK,
as an energy sensor, could block cellular proliferation and
synthesis of cholesterol or fatty acid7, but stimulate glucose uptake
and autophagy8,9. Due to its signiﬁcant sensor role in modulating
pathways in catabolic processes, AMPK inhibition is correlated
with endocrine metabolic conditions, including diabetes and its
induced complications. Signaling pathways affected by inhibition
AMPK have been studied extensively in diabetes and its compli-
cations, such as autophagy, mitochondrial biogenesis and energy
regulation. In the present review, we will focus on the important
role of AMPK and autophagy in diabetes and its complications.1.2. Introduction of autophagy
Autophagy, a kind of intracellular recycling system, is the basic
catabolism activated by lysosomes or autolysosomes, including
degradation of dysfunctional or unnecessary cellular organelles
and nutrients2,10. It has been reported that autophagy plays an
important role in the regulation of catabolic nutrients; when
nutrients are abundant, insulin secretion would be stimulated.
But when nutrients are lacking autophagy might be evoked at a
cellular level11. Autophagy could be induced by oxidative stress or
any other cellular injuries and loss. There are three types of
autophagy, involving macroautophagy, microautophagy and
chaperone-mediated autophagy. The macroautophagy involving
fusion with lysosomes is the common autophagy, which is also
what we will review below.
Autophagy could be regulated by several factors and protein
sensors, including amino acids or insulin. Autophagy induced by
another condition of nutrient starvation like glucose deprivation is
less common12, but they are all associated with signaling path-
ways. Generally, besides the positive effects supported by few
researches, negative effect, inhibited by mammalian target of
rapamycin (mTOR) complex 1 (mTORC1) seems to be more
related to glucose deprivation of autophagy13. It should be clariﬁed
that mTORC1 is a signaling complex, which involves mTOR,
RAPTOR (regulator associated protein of mTOR), PRAS40 (pro-
line-rich Akt substrate 40 kDa), DEPTOR (DEP domain-
containing mTOR-interacting protein) and LST8 homolog (mTOR
associated protein)14. The upstream regulatory factors respond to
ATP depletion (AMPK, P53), reactive oxygen species [janus
kinase (JNK), extracellular signal-regulated kinase (ERK)] and
directly induction of glucose deprivation [forkhead box class O
(FoxO), IκB kinase (IKK)]. Furthermore, the direct up-regulatory
kinase could be serine/threonine protein kinase Unc-51-like kinase
1 (ULK1) and Beclin1-BCL2 complex. For instance, ULK1 could
be phosphorylated at Ser317 and Ser777 to induce autophagy. AndBeclin1 could also be phosphorylated to block the forming of the
Beclin1-BCL2 complex, which would inhibit autophagy. Like-
wise, microtubule-associated protein 1 A/1B-light chain 3 (LC3) is
an autophagosomal marker and one of the important measurement
indicators, which could reﬂect the status of autophagic activity
induced by starvation5. Thus, AMPK and autophagy will be
summarized with regard to the mechanism of upstream and
downstream modulation in classic pathways.
1.3. The mechanism of AMPK-regulated autophagy
AMPK is a major activator of autophagy in the catabolic process
of oxidative stress and energy starvation. Their modulation has
been concluded in a few classic pathways. In previous studies
autophagy was just thought to play a dual role in either avoiding
cell death in some conditions or inducing autophagic death15.
After a few years, it has been linked with protein kinase-AMPK
activation directly and indirectly. AMPK could activate autophagy
by directly activating ULK1. Speciﬁcally, AMPK and mTORC1
are both initiators of autophagy via ULK1 activation9. AMPK
could active ULK1 by phosphorylation not only at Ser317,
Ser777, but also at Ser467, Ser555, Ser637 and Thr5748, while
ULK1 is inhibited by mTORC1 phosphorylation at Ser317 and
Ser777. To some extent, AMPK activity could be suppressed by
mTORC1 via increased phosphorylation of ULK1 at Ser7579,14.
AMPK could activate autophagy indirectly by tuberous sclerosis
complex 2 (TSC2) phosphorylation and subsequent mTORC1
inhibition16 (Fig. 1). Moreover, activation of AMPK also could
stimulate JNK1 following dissociation of Beclin-1 from BCL-2 to
form vacuolar protein-sorting 34 (VPS34) complex17 and turn on
autophagy. Other studies also reported that AMPK modulates
FoxO transcription factor expression, which leads to expression of
autophagy-associated genes14. Thus, AMPK is a key junction as
both an upstream energy sensor and a downstream autophagy
activator, especially in endocrine disordered diseases such as
diabetes.2. The regulation of autophagy by AMPK in diabetes and its
complications
2.1. AMPK and autophagy in pancreatic β cells
The pancreatic β cell in pancreatic islets is a signiﬁcant glucose
regulatory cell regard to insulin secretion. Pancreatic islets are also
correlated with lipid metabolism. When disordered pancreatic islet
or dysfunctional pancreatic β cells occur, it is always related to
abnormal glucose and lipid levels18. Additionally, Dong and Czaja
or Singh et al.19,20 have reported that intracellular lipid droplets
might be one substrate of autophagy. In the process of lipid
overloading, autophagy could metabolize lipid by moving the
unnecessary part. Because activated autophagy might not only
alleviate endoplasmic reticulum stress, but also restart the process
of lipophagy for pancreatic islets protection21. Cellular level
studies in pancreatic β cells also show that autophagy plays a
pivotal role. The relative pathway might contain LC3, PKC
(protein kinase C), JNK as well as others22–24. Moreover, in
normal conditions, metformin could suppress Min6 β cell pro-
liferation and promote cell apoptosis through an AMPK indepen-
dent and autophagic mechanism. However, as an effective anti-
diabetic drug, metformin could protect pancreatic β cells in
particular from the apoptosis induced by palmitic acid22. Another
Figure 1 Autophagy stimulated by AMPK activation contains four normal pathways found till now. When energy is insufﬁcient, AMPK could
phosphorylate JNK, ULK1, TSC1/2 and FoxO transcription factor to activate autophagy in many tissues generally. And the upstream pathways in
autophagy activity regulation also contain BCL2 inhibition, Beclin1 stimulation and mTORC1 blocking.
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shown to reduce lipid accumulation in pancreatic β cells and lead
to autophagy via protection of AMPK activation. The study
demonstrated that JLDG might not only inhibit lipogenesis by
downregulation of acetyl coenzyme A carboxylase (ACC) and so
on, but also reduce the expression of mTOR and stimulate
expression of tuberous sclerosis complex 1 (TSC1) and LC3 to
induce the autophagy18. Except the protective mechanism, Chen
et al.23 have argued that as an adaptive response, β cell autophagy
could inhibit increased insulin resistance. Take the diabetic fatty
mouse model as an example: it has been found that autophagy was
necessary to maintain the normal architecture of islets and
intracellular insulin metabolism by increasing the insulin degrada-
tion rate in β bells of the Rab3A / null mouse. Altered
autophagy might also induce loss of pancreatic β cell mass in
diabetes23,25. Nonetheless, decreasing beclin1 expression could
protect Min6 cells to some extent. It has been reported that a
certain degree of autophagy is essential for Min6 cell survival26.
So the mechanism and regulation is between autophagy and
autophagic cell death. But whether autophagy could boost cell
death or regulate cell survival of pancreatic β cells and diabetes
therapy need to be elucidated. The evidence nonetheless indicates
that autophagy could play an essential protective role in glucose
starvation via AMPK stimulation.
2.2. AMPK and autophagy in muscle insulin sensitivity
Skeletal muscle insulin sensitivity can be improved by physical
exercise, which reduces the risk of diabetes and cardiovascular
disease27. Intensity and duration of exercise might determine the
status of AMPK activation, which has a strong relationship with
the increasing status of insulin sensitivity24. Likewise, it has been
found that autophagy could modulate glucose homeostasis in
skeletal muscle and increase insulin sensitivity. So there is a link
between AMPK and autophagy in exercise and insulin sensitivity
in skeletal muscle. Firstly, one study has shown that mutation of
AMPK sucrose non-fermenting 1 (SNF1) gene might induceddefective energy metabolism in the yeast and ATG1 and ATG13,
which are autophagy related protein kinases, are also involved in
this regulation18,27. Liu et al.10 have also reported that muscle-
speciﬁc AMPKα2-deﬁcient mice, which lost AMPKα2, could
impair activation of autophagy in muscle exercise, suggesting that
stimulation of AMPK is essential for muscle autophagy induced
by physical exercise. The possible pathway might include the
Beclin1-BCL2 complex. Furthermore, BCL2 mutant mice research
has proved that autophagy is a critical regulator in metabolism
related exercise, and this is correlated with insulin resistance. For a
detailed pathway, AMPK phosphorylated FoxO3 to induce the
expression of LC3, beclin1 in skeletal muscle, which is associated
with autophagy28. AMPK could interact with ULK1 directly to
stimulate autophagy as described above10. Additionally, dihydro-
myricetin, which is a natural ﬂavonoid, has been shown to
improved skeletal muscle insulin resistance by stimulation of
autophagy through AMPK-beclin1 or LC3 pathways. And the
AMPK inhibitor compound C has been used to prove that the
autophagy was induced by AMPK, because the blocking of
AMPK suppressed the activation of autophagy and the improve-
ment in skeletal muscle insulin resistance29. Therefore, several
study results have demonstrated that AMPK activates autophagy to
increase insulin sensitivity in skeletal muscle, and AMPK is a
necessary sensor in these modulation processes.
2.3. AMPK and autophagy in liver gluconeogenesis
Liver, another glucose metabolic organ, can play a role in
suppressing hyperglycemia. There are two mechanisms to decrease
glucose production in liver to inﬂuence metabolism and diabetes.
One is to activate glycolysis or increase the synthesis of glycogen,
protein and lipid, and another is to inhibit glycogenolysis,
gluconeogenesis, proteolysis or lipolysis30. AMPK and autophagy
can participate in glucose regulation of liver. On one hand, AMPK
could suppress ACC to be a rate-limiting step for lipogenesis by
liver via accelerating oxidation of long chain fat acids and
inhibiting insulin-mediated lipid synthesis. On the other hand,
AMPK improves autophagy activity 23activation of AMPK could lead to autophagy improvement, which
would be decreased in liver hyperglycemia30,31. So autophagy
might be related to lipid synthesis in liver. There are two possible
ways to affect lipid synthesis with regard to AMPK, including
liver kinase B1 (LKB1) and Ca2þ calmodulin-dependent protein
kinase kinase (CaMKK). To be speciﬁc, LKB1 might stimulate
AMPK to translocate to cytosol. In mouse hepatocytes, adaptor
protein containing pleckstrin homology domain, phosphotyrosine,
interaction, pH domain and leucine zipper motif 1 (APPL1) could
combine with adiponectin receptors 1 and 2 (AdipoR1 and
AdipoR2) at N-terminal domains, which induced LKB1 cytosolic
localization for AMPK activation32,33. Moreover, AdipoR1 and
AdipoR2 binding could promote APPL1 homodimerization34. For
the CaMKK pathway, it binds the similar signiﬁcant sequence and
shares structural homology with LKB1 to be the upregulator for
AMPK, which could be activated by adiponectin trimers30,35–37. In
addition, adiponectin could also decrease autophagy via AMPK in
the liver. This inhibition of autophagy was known as suppressor of
glucose form autophagy (SOGA)38,39. One relative study reported
that SOGA knockdown might activate autophagy or proteolysis to
prevent hepatocytes glucose production by adiponectin stimula-
tion40,41. Another experiments conducted by Kundu et al.42
demonstrated that hyperglycemia impairs AMPK phosphorylation,
which depended on LKB1 and CaMKK activation. Inactive
AMPK also inhibited autophagy through mTOR upregulation
and accumulation of matrix protein. In addition, the downstream
regulation is similar with the normal autophagy activation pathway
like AMPK-ULK143. So LKB1, CaMKK and SOGA could be the
more signiﬁcant discovery as the present potential sensors for
AMPK and autophagy glucose production or lipid synthesis in
hepatocytes, especially in hyperglycemic liver. Autophagy plays a
positive protective role in liver glucose and lipid regulation in
metabolic diseases as well.2.4. AMPK and autophagy in diabetic cardiomyopathy
Diabetic cardiomyopathy has become a major cause of diabetes-
related morbidity and mortality. It is characterized by ventricular
dysfunction that develops in diabetic patients without coronary
artery disease or hypertension. Autophagy has been known as an
important myocardial adaptive response to conserve energy.
Dieter et al.14 reported that improving cardiac autophagy in
patients with diabetes might prevent the impact of diabetic
cardiomyopathy development. Restoration of autophagy could
block the accumulation of dysfunctional organelles and cytotoxic
protein aggregates. Autophagy is strongly controlled by the
mammalian target of rapamycin (mTOR)-dependent signaling
pathway. Most cardiac studies conﬁrm that mTOR is a negative
regulator of autophagy as well (via mTORC1-ULK1/2 phosphor-
ylation or mTORC2-Akt-FoxO phosphorylation). Inhibition of
mTOR is linked to autophagy induction in isolated cardiomyo-
cytes and myocardial tissue44,45. The AMPK-mTOR pathway has
been considered an important mechanism in autophagy regulation
in response to energy stress and glucose starvation. In mammals,
compromised cellular energy production inhibits mTOR through
activation of AMPK and subsequently, phosphorylation of the
TSC. Since mTOR negatively regulate autophagy, it is likely that
diabetes activates TSC-mTOR signaling through inactivation of
AMPK, which inhibits the ULK kinase complex, preventing the
initiation of autophagy. Nonetheless, over activation of autophagy
in diabetes has also been found to be harmful to development ofcardiomyopathy and cardiac function to induce excessive cell
stress46. Whether the autophagy in cardiomyocytes should be a
protective or detrimental mechanism is still a debate at this time47.
Therefore, it might be better to balance the status of autophagy
activation in diabetic cardiomyopathy. Besides autophagy of
cardiomyocytes, myocardial ﬁbroblasts have also been mentioned
in the rapamycin-regulated process of diabetic cardiomyopathy.
However, most studies of pathological myocardial ﬁbroblasts
focused on cell apoptosis, extracellular matrix increasing, expres-
sion of collagen increasing and so on. There are no original reports
about autophagy dysfunction of myocardial ﬁbroblasts in diabetic
cardiomyopathy. Additionally, according to the pathological
process of hepatic ﬁbrosis and renal ﬁbrosis, autophagy is involved
in increasing extracellular matrix and collagen degradation. Thus
autophagy dysfunction of myocardial ﬁbroblasts in cardiomyo-
pathy or myocardial ﬁbrosis might be a potential mechanism of
diabetic cardiomyopathy, and a critical point and a target for
diabetic cardiomyopathy treatment44.2.5. AMPK and autophagy in diabetic nephropathy
Diabetic nephropathy (DN) is a serious complication of diabetes.
In the early stages of diabetes, patients exhibit hyperﬁltration with
high glomerular ﬁltration rates (GFRs) and infrequent occurance of
microalbuminuria. Glomerular damage, along with proteinuria,
and subsequent tubulointerstitial lesions induced by diabetes
ﬁnally lead to end stage renal disease48. Several studies have
suggested that autophagy is involved in the pathogenesis of DN.
AMPK as a regulator of autophagy has also been suggested to be
involved in the pathogenesis of DN. It has been reported that
podocytes and proximal tubular cells are the main cells affected in
DN. Autophagy plays a crucial role in maintaining the function of
podocytes and proximal tubular cells. Fang et al.49 reported that in
high-glucose conditions in cultured podocytes and streptozotocin
(STZ)-induced type 1 diabetic rats, autophagy was suppressed
with a decrease of the expression of Beclin-1, ATG12-5, and LC3,
and lead to the impaired ﬁltration barrier function of podocytes.
Interestingly, Cina et al.50 reported that mTORC1 is highly
activated and may be involved in the mechanisms of autophagy
inhibition in podocytes of diabetic mice and patients. In addition,
several studies have reported that AMPK activation by AICAR or
adiponectin shows podocyte protective effects against various
nephrotoxic conditions. It seems that autophagy activation is
intricate in AMPK-mediated podocyte protection. AMPK can
activate autophagy via two independent mechanisms: suppression
of mTORC1 activity and direct control of ULK1 phosphorylation.
Between these two independent mechanisms of AMPK on the
regulation of autophagy, suppression of mTORC1 activity might
contribute to the protection of AMPK in podocytes of DN.
Furthermore, the results from Yamahara et al.51 suggested that
hyperactivation of mTORC1 signaling in proximal tubular cells
was involved in obesity-mediated autophagy suppress. However,
proximal tubular cells are correlated with SIRT1 (sirtuin type 1) or
p62/SQSTM1 (sequestosome 1) protein in autophagy. As an
example, in proximal tubular cells accumulation of p62/SQSTM1
protein occurred in type 2 diabetes patients, which suggested that
deﬁciency of autophagy might affect diabetic kidney disease in
humans48,51. These ﬁndings lead us to hypothesize that autophagy
is altered in diabetic kidneys, and autophagy deﬁciency should
contribute to the pathogenesis of diabetic nephropathy, related
with not only podocytes but also proximal tubular cells. Therefore,
Figure 2 Activation of autophagy could occur in several diabetes-related diseases, including pancreatic β cells, muscle insulin sensitivity and
liver gluconeogenesis related syndromes or diabetes cardiomyopathy and diabetes nephropathy. Subsequently, mTORC1 and TSC1 expression
were included in the regulation of pancreatic β cells. In skeletal muscle, ULK1 or FoxO3 and LC3 might affect insulin sensitivity as well as in liver
gluconeogenesis, which has a strong association with autophagy activation. Additionally, LKB1, CAMKK and SOGA are the special sensors
involved in liver gluconeogenesis studied recently. And AMPK-RHEB-TOC1 is the signiﬁcant signaling pathway in diabetes cardiomyopathy and
nephropathy. All of these are linked with energy sensor, AMPK.
Fan Yao et al.24if pharmacological AMPK activation really acts as an autophagy
activator, a drug that stimulates AMPK may be a potential therapy
for diabetic nephropathy52. Several studies have reported that
AMPK activation shows renoprotective effects in diabetic nephro-
pathy. Autophagy may be involved in AMPK mediated renopro-
tective action.3. Conclusions and perspective
It has been found for diabetes mellitus that autophagy is a
signiﬁcant factor with AMPK, an important regulatory signaling
pathway. The autophagy induced by cellular lesions could affect a
variety of tissues, glucose or lipid metabolism and insulin
secretion. Hence, these conditions might lead to serious chronic
disease as diabetes complications (Fig. 2). At times, diabetes itself
may not be such a serious status. But continuing or additional
tissue damage could lead to a critical mass of cell injuries and
imbalance homeostasis. Accordingly, autophagy induced by
AMPK is involved in calorie production and lipogenesis mainly
with other protein signals, such as mTOC1, LKB1, ULK and LC3.
The crosstalk between autophagy and AMPK might be a possible
therapeutic target. In future research, blocking other regulatory
pathways of autophagy like mTOC1 might be signiﬁcant, includ-
ing AMPK upstream and downstream regulation. Likewise, in
recent decades, medicine, therapeutic approaches and pathogenesis
would tend to depend on individuals. Therefore, combining with
genetic and protein levels in AMPK and autophagy stimulation
pathways might be a tendency for diabetes and complications
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